Skip to content

Author

Yusuke Sakai

We have 4 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Eosinophil-driven immunopathology exacerbates SARS-CoV-2 pneumonia in an OVA-induced airway allergy mouse model

ABSTRACT Asthma is an allergic airway disease characterized by distinct immune environments that can alter host responses to respiratory viral infections; however, its impact on coronavirus disease 2019 (COVID-19) severity remains unclear. To investigate how allergic airway inflammation affects severe acute respiratory...

Takao Iketani, N. Iwata-Yoshikawa, Yusuke Sakai et al. · 0 citations
Open access Oct 2026

Persistent SARS-CoV-2 infection in SCID rats reflects immune vulnerability of the upper airway and trachea

ABSTRACT In immunocompromised patients, persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries the risk of prolonged viral shedding and emergence of new variants. To reproduce the key features of persistent SARS-CoV-2 infection and evaluate its transmissibility, mouse-passaged SARS-Co...

Kaya Miyazaki, Nozomi Shiwa-Sudo, N. Iwata-Yoshikawa et al. · 0 citations
Review Sep 2026

Emerging tick-borne viral diseases in East Asia: pathology-driven insights into pathogenesis and disease causality

This review provides a comprehensive synthesis of tick-borne viral infections in East Asia, with particular emphasis on Japan, integrating pathological, virological, and clinical perspectives and underscores the importance of a synergistic One Health framework that incorporates both human and veterinary pathology to ad...

Yuichiro Hirata, Yusuke Sakai, Tadaki Suzuki · 0 citations
Aug 2026

A novel candidate vaccine virus derived from Japan's first mammalian case of clade 2.3.4.4b A/H5N1 highly pathogenic avian influenza virus.

Overall, NIID-002 fulfills the key requirements for the pandemic preparedness of CVV, combining reduced pathogenicity, broad antigenic reactivity, and adequate production efficiency, which underscores the continued need for surveillance and refinement of influenza vaccine strategies to address evolving viral threats.

Yasushi Suzuki, Tomoko Arita, Masayuki Shirakura et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.